サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1553664

スポーツ医学向け血液ベースバイオマーカーの市場規模、シェア、動向分析レポート：タイプ別、地域別、セグメント予測、2024年～2030年

Blood-based Biomarker For Sports Medicine Market Size, Share & Trends Analysis Report By Type (CK, Myoglobin, Lactate, WBC, Urea, CRP), By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 105 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
スポーツ医学向け血液ベースバイオマーカーの市場規模、シェア、動向分析レポート：タイプ別、地域別、セグメント予測、2024年～2030年
出版日: 2024年08月28日
発行: Grand View Research
ページ情報: 英文 105 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

スポーツ医学向け血液ベースバイオマーカー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、スポーツ医学向け血液ベースバイオマーカーの世界市場規模は2030年までに11億6,000万米ドルに達すると予測され、2024年から2030年までのCAGRは6.7％で拡大すると予測されています。

この市場を牽引する主な要因は、個別化された健康への注目の高まり、バイオマーカー技術の進歩、正確なパフォーマンス＆回復評価への需要の高まりです。さらに、スポーツ関連傷害に対する意識の高まりと精密診断の必要性も、市場の成長と革新に寄与しています。

研究開発重視の高まりとスポーツ医学への投資の増加は、市場の拡大を大きく後押ししています。スポーツ医学分野の発展に伴い、先進的なバイオマーカーを通じてアスリートの複雑な生理学的反応を理解することに注目が集まっています。スポーツ医学研究への投資は、血液ベースのバイオマーカー技術の著しい進歩を促進しています。企業や研究機関は、バイオマーカーの検出と解釈を改善するために、ハイスループット・スクリーニング法や高度なデータ分析の開発に多額の投資を行っています。公的機関や民間組織からの投資の増加は、スポーツ医学における高度バイオマーカーの需要をさらに促進しています。

さらに、傷害リスクを事前に予測するために、バイオマーカーの予測可能性も研究されています。Frontiers in Physiology誌に掲載された調査によると、先進的な研究では、傷害感受性を予測するための酸化ストレスと炎症のバイオマーカーに焦点が当てられています。この予測能力は予防戦略にとって価値があり、アスリートが事前対策によって怪我を回避するのに役立ちます。その結果、スポーツ医学における血液ベースのバイオマーカー市場は大きな成長を遂げています。

スポーツ医学向け血液ベースバイオマーカー市場レポート・ハイライト

  • クレアチンキナーゼ（CK）セグメントは2023年に18.0％で最大の収益シェアを占めました。CK検査の需要は、傷害の予防と管理に重点が置かれるようになり、オーバートレーニングの防止と回復の最適化の重要性に対するアスリート＆スポーツチームの意識が高まっていることが背景にあります。
  • スポーツ医学用血液ベースバイオマーカー市場で事業を展開している主要企業には、Abbott、BIOMERIEUX、F. Hoffmann-La Roche Ltd.、ARUP Laboratories、Siemens Healthineers AG、RayBiotech, Inc.などがあります。さらに、新興国市場では、新規参入企業による革新的な新製品の登場や、新たな製品を開発するための主な市場参入企業間の戦略的提携が見られます。
  • 2023年3月、アボット社は米国FDAからTBIのための初の市販血液検査の認可を取得し、米国の病院で広く利用できるようになった。この検査は血液中の2つのバイオマーカーを検出するもので、これらのバイオマーカーが高値で存在する場合、脳損傷と強く関連します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 スポーツ医学向け血液ベースバイオマーカー市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • スポーツ医学向け血液ベースバイオマーカー市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • パイプライン分析

第4章 スポーツ医学向け血液ベースバイオマーカー市場：タイプ別推定・動向分析

  • 世界のスポーツ医学向け血液バイオマーカー市場：タイプ別ダッシュボード
  • 世界のスポーツ医学向け血液バイオマーカー市場：タイプ別変動分析
  • 世界のスポーツ医学向け血液バイオマーカー市場：タイプ別収益
  • CK
  • ミオグロビン
  • 乳酸
  • 白血球数
  • 尿素
  • ＣＲＰ
  • 脂質およびタンパク質のヒドロペルオキシド
  • IL-6
  • その他

第5章 スポーツ医学向け血液ベースバイオマーカー市場：タイプ別の地域別推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第6章 競合情勢

  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析、2023年
    • Abbott
    • BIOMERIEUX
    • F. Hoffmann-La Roche Ltd.
    • ARUP Laboratories
    • Siemens Healthineers AG
    • RayBiotech, Inc.
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc.
    • Beckman Coulter, Inc.
    • Randox Laboratories Ltd.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 5 Canada blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 6 Mexico blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 7 Europe blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 8 Europe blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 9 Germany blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 10 UK blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 11 France blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 12 Italy blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 13 Spain blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 14 Denmark blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 15 Sweden blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 16 Norway blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 19 China blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 20 New Zealand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 21 Taiwan blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 22 Hong Kong blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 23 Singapore blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 24 Thailand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 25 Vietnam blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 26 Japan blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 27 India blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 28 South Korea blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 29 Australia blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 30 New Zealand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 31 Latin America blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 32 Latin America blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 33 Brazil blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 34 Argentina blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 35 Chile blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 36 MEA blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 37 MEA blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 38 South Africa blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 39 Saudi Arabia blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 40 UAE blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 41 Egypt blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 42 Qatar blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Blood-based biomarker for sports medicine market: market outlook
  • Fig. 14 Blood-based biomarker for sports medicine competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Blood-based biomarker for sports medicine market driver impact
  • Fig. 18 Blood-based biomarker for sports medicine market restraint impact
  • Fig. 19 Blood-based biomarker for sports medicine market: Type movement analysis
  • Fig. 20 Blood-based Biomarker for Sports Medicine market: Type outlook and key takeaways
  • Fig. 21 CK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Myoglobin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Lactate market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 WBC market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Urea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 CRP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Lipid and protein hydroperoxides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 IL-6 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Global blood-based biomarker for sports medicine market: Regional movement analysis
  • Fig. 31 Global blood-based biomarker for sports medicine market: Regional outlook and key takeaways
  • Fig. 32 Global blood-based biomarker for sports medicine market share and leading players
  • Fig. 33 North America, by country
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. key country dynamics
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada key country dynamics
  • Fig. 38 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico key country dynamics
  • Fig. 40 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK key country dynamics
  • Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Germany key country dynamics
  • Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France key country dynamics
  • Fig. 47 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Italy key country dynamics
  • Fig. 49 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Spain key country dynamics
  • Fig. 51 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark key country dynamics
  • Fig. 53 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden key country dynamics
  • Fig. 55 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Norway key country dynamics
  • Fig. 57 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 China key country dynamics
  • Fig. 60 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Japan key country dynamics
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 New Zealand key country dynamics
  • Fig. 66 New Zealand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea key country dynamics
  • Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Taiwan key country dynamics
  • Fig. 72 Taiwan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Hong Kong key country dynamics
  • Fig. 74 Hong Kong market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Singapore key country dynamics
  • Fig. 76 Singapore market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Thailand key country dynamics
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Vietnam key country dynamics
  • Fig. 80 Vietnam market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Brazil key country dynamics
  • Fig. 83 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Argentina key country dynamics
  • Fig. 85 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Chile key country dynamics
  • Fig. 87 Chile market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa key country dynamics
  • Fig. 90 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Saudi Arabia key country dynamics
  • Fig. 92 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 UAE key country dynamics
  • Fig. 94 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Egypt key country dynamics
  • Fig. 96 Egypt market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Qatar key country dynamics
  • Fig. 98 Qatar market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Market share of key market players- blood-based biomarker for sports medicine market
目次
Product Code: GVR-4-68040-436-1

Blood-Based Biomarker For Sports Medicine Market Growth & Trends:

The global blood-based biomarker for sports medicine market size is anticipated to reach USD 1.16 billion by 2030 and is anticipated to expand at a CAGR of 6.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing focus on personalized health, advancements in biomarker technology, and growing demand for accurate performance & recovery assessments. Moreover, rising awareness of sports-related injuries and the need for precise diagnostics also contribute to market growth & innovation.

The growing emphasis on R&D and rising investments in sports medicine are significantly driving the market expansion. As the sports medicine field evolves, there is an increasing focus on understanding the complex physiological responses of athletes through advanced biomarkers. Investment in sports medicine research is promoting significant advancements in blood-based biomarker technologies. Companies and research institutions are investing heavily in developing high-throughput screening methods and advanced data analytics to improve biomarker detection and interpretation. The growing investment from public and private organizations further propels the demand for advanced biomarkers in sports medicine.

Moreover, the predictive potential of biomarkers is also being investigated to predict injury risks before they occur. According to research published in Frontiers in Physiology, advanced research focuses on oxidative stress and inflammation biomarkers to predict injury susceptibility. This predictive capability is valuable for preventive strategies, helping athletes avoid injuries through proactive measures. As a result, the market for blood-based biomarkers in sports medicine is experiencing significant growth.

Blood-Based Biomarker For Sports Medicine Market Report Highlights:

  • The creatine kinase (CK) segment accounted for the largest revenue share at 18.0% in 2023. The demand for CK testing is driven by the increasing focus on injury prevention and management and increasing awareness among athletes & sports teams about the importance of preventing overtraining and optimizing recovery
  • Some of the key players operating in the blood-based biomarkers for sports medicine market are Abbott, BIOMERIEUX, F. Hoffmann-La Roche Ltd., ARUP Laboratories, Siemens Healthineers AG, and RayBiotech, Inc. Furthermore, the market is witnessing the emergence of new and innovative products from new players, as well as strategic partnerships among key market players to develop new offerings
  • In March 2023, Abbott obtained clearance from the U.S. FDA for the first commercially available laboratory blood test for TBI, allowing it to be widely accessible in U.S. hospitals. The test detects two biomarkers in the blood, which, when present at elevated levels, are strongly associated with brain injury

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood-based Biomarker for Sports Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing Demand for Personalized Medicine
      • 3.2.1.2. Increased Focus on Injury Prevention and Recovery
      • 3.2.1.3. Growing R&D and Rising Investments in Sports Medicine s
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory Challenges and Lack of Awareness & Standardization
  • 3.3. Blood-based Biomarker for Sports Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Blood-based Biomarker for Sports Medicine Market: Type Estimates & Trend Analysis

  • 4.1. Global Blood-based Biomarker for Sports Medicine Market: Type Dashboard
  • 4.2. Global Blood-based Biomarker for Sports Medicine Market: Type Movement Analysis
  • 4.3. Global Blood-based Biomarker for Sports Medicine Market by Type, Revenue
  • 4.4. CK
    • 4.4.1. CK market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Myoglobin
    • 4.5.1. Myoglobin market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Lactate
    • 4.6.1. Lactate market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. WBC
    • 4.7.1. WBC market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.8. Urea
    • 4.8.1. Urea market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.9. CRP
    • 4.9.1. CRP market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.10. Lipid and Protein Hydroperoxides
    • 4.10.1. Lipid and protein hydroperoxides market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.11. IL-6
    • 4.11.1. IL-6 market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.12. Others
    • 4.12.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Blood-based Biomarker for Sports Medicine Market: Regional Estimates & Trend Analysis by Type

  • 5.1. Regional Dashboard
  • 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.3. North America
    • 5.3.1. U.S.
      • 5.3.1.1. Key country dynamics
      • 5.3.1.2. Regulatory framework/ reimbursement structure
      • 5.3.1.3. Competitive scenario
      • 5.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.3.2. Canada
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.3.3. Mexico
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Key country dynamics
      • 5.4.1.2. Regulatory framework/ reimbursement structure
      • 5.4.1.3. Competitive scenario
      • 5.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.3. France
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.6. Norway
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.3. India
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.5. New Zealand
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. New Zealand market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.6. Taiwan
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Taiwan market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.7. Hong Kong
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework/ reimbursement structure
      • 5.5.7.3. Competitive scenario
      • 5.5.7.4. Hong Kong market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.8. Singapore
      • 5.5.8.1. Key country dynamics
      • 5.5.8.2. Regulatory framework/ reimbursement structure
      • 5.5.8.3. Competitive scenario
      • 5.5.8.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.9. Thailand
      • 5.5.9.1. Key country dynamics
      • 5.5.9.2. Regulatory framework/ reimbursement structure
      • 5.5.9.3. Competitive scenario
      • 5.5.9.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.10. Vietnam
      • 5.5.10.1. Key country dynamics
      • 5.5.10.2. Regulatory framework/ reimbursement structure
      • 5.5.10.3. Competitive scenario
      • 5.5.10.4. Vietnam market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.2. Argentina
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.3. Chile
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. Chile market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.4. Egypt
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. Egypt market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.5. Qatar
      • 5.7.5.1. Key country dynamics
      • 5.7.5.2. Regulatory framework/ reimbursement structure
      • 5.7.5.3. Competitive scenario
      • 5.7.5.4. Qatar market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company/Competition Categorization
  • 6.2. Vendor Landscape
    • 6.2.1. List of key distributors and channel partners
    • 6.2.2. Key customers
    • 6.2.3. Key company market share analysis, 2023
    • 6.2.4. Abbott
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. BIOMERIEUX
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd.
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. ARUP Laboratories
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. Siemens Healthineers AG
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. RayBiotech, Inc.
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Thermo Fisher Scientific, Inc.
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Bio-Rad Laboratories, Inc.
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives
    • 6.2.12. Beckman Coulter, Inc.
      • 6.2.12.1. Company overview
      • 6.2.12.2. Financial performance
      • 6.2.12.3. Product benchmarking
      • 6.2.12.4. Strategic initiatives
    • 6.2.13. Randox Laboratories Ltd.
      • 6.2.13.1. Company overview
      • 6.2.13.2. Financial performance
      • 6.2.13.3. Product benchmarking
      • 6.2.13.4. Strategic initiatives